Citadel Advisors’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-393,296
| Closed | -$68.3K | – | 15585 |
|
|
2023
Q1 | $62.9K | Buy |
+393,296
| New | +$175K | ﹤0.01% | 11864 |
|
|
2022
Q3 | – | Sell |
-421,901
| Closed | -$455K | – | 13976 |
|
|
2022
Q2 | $267K | Buy |
421,901
+318,596
| +308% | +$245K | ﹤0.01% | 10080 |
|
|
2022
Q1 | $117K | Sell |
103,305
-110,399
| -52% | -$132K | ﹤0.01% | 12115 |
|
|
2021
Q4 | $480K | Sell |
213,704
-28,063
| -12% | -$70.4K | ﹤0.01% | 9797 |
|
|
2021
Q3 | $827K | Buy |
241,767
+161,520
| +201% | +$498K | ﹤0.01% | 8618 |
|
|
2021
Q2 | $240K | Sell |
80,247
-297,265
| -79% | -$940K | ﹤0.01% | 11780 |
|
|
2021
Q1 | $1.22M | Buy |
+377,512
| New | +$1.26M | ﹤0.01% | 7609 |
|
|
2020
Q2 | – | Sell |
-16,165
| Closed | -$14K | – | 10698 |
|
|
2020
Q1 | $14K | Sell |
16,165
-29,219
| -64% | -$33.9K | ﹤0.01% | 9375 |
|
|
2019
Q4 | $44K | Buy |
45,384
+17,950
| +65% | +$19.7K | ﹤0.01% | 8791 |
|
|
2019
Q3 | $28K | Sell |
27,434
-2,557
| -9% | -$3.48K | ﹤0.01% | 8867 |
|
|
2019
Q2 | $54K | Sell |
29,991
-30,694
| -51% | -$49.4K | ﹤0.01% | 8706 |
|
|
2019
Q1 | $114K | Sell |
60,685
-35,102
| -37% | -$51.4K | ﹤0.01% | 8499 |
|
|
2018
Q4 | $113K | Buy |
95,787
+59,909
| +167% | +$108K | ﹤0.01% | 8199 |
|
|
2018
Q3 | $97K | Buy |
+35,878
| New | +$74.2K | ﹤0.01% | 8590 |
|
|
2018
Q2 | – | Sell |
-21,511
| Closed | -$43.5K | – | 9425 |
|
|
2018
Q1 | $45K | Buy |
21,511
+7,340
| +52% | +$15.7K | ﹤0.01% | 7957 |
|
|
2017
Q4 | $29K | Buy |
14,171
+3,581
| +34% | +$7.43K | ﹤0.01% | 7774 |
|
|
2017
Q3 | $14K | Sell |
10,590
-6,614
| -38% | -$8.21K | ﹤0.01% | 7420 |
|
|
2017
Q2 | $27K | Sell |
17,204
-69,318
| -80% | -$134K | ﹤0.01% | 7233 |
|
|
2017
Q1 | $279K | Buy |
86,522
+70,678
| +446% | +$174K | ﹤0.01% | 5985 |
|
|
2016
Q4 | $21K | Sell |
15,844
-11,407
| -42% | -$14.9K | ﹤0.01% | 7077 |
|
|
2016
Q3 | $43K | Buy |
+27,251
| New | +$41.9K | ﹤0.01% | 6880 |
|
|
2015
Q4 | – | Sell |
-39,100
| Closed | -$330K | – | 9342 |
|
|
2015
Q3 | $330K | Buy |
+39,100
| New | +$361K | ﹤0.01% | 5423 |
|
|
2015
Q2 | – | Sell |
-531,294
| Closed | -$6.82M | – | 9189 |
|
|
2015
Q1 | $7.43M | Buy |
531,294
+83,047
| +19% | +$1.27M | 0.01% | 1672 |
|
|
2014
Q4 | $7.57M | Buy |
448,247
+416,395
| +1,307% | +$6.06M | 0.01% | 1623 |
|
|
2014
Q3 | $427K | Buy |
+31,852
| New | +$379K | ﹤0.01% | 4827 |
|
|
2014
Q1 | – | Sell |
-31,941
| Closed | -$429K | – | 8066 |
|
|
2013
Q4 | $441K | Sell |
31,941
-190,860
| -86% | -$2.7M | ﹤0.01% | 4166 |
|
|
2013
Q3 | $3.89M | Buy |
222,801
+155,887
| +233% | +$2.99M | 0.01% | 1784 |
|
|
2013
Q2 | $1.09M | Buy |
+66,914
| New | +$2.07M | ﹤0.01% | 3114 |
|
Other funds holding INFI
Citadel Advisors's INFI Position: Q2 2023 in Review
Citadel Advisors sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2023, closing a stake of 393,296 shares — an estimated $68.3K sold.
Citadel Advisors first reported a position in INFI in Q2 2013 and held it in 28 quarters. The position peaked at $7.57M in Q4 2014. 45 funds tracked by Wall St. Rank hold INFI as of Q2 2023.
- Citadel Advisors reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
- Citadel Advisors sold 393,296 Infinity Pharmaceuticals, Inc. shares in Q2 2023, an estimated $68.3K.
- Citadel Advisors first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 28 quarters.
- Citadel Advisors's Infinity Pharmaceuticals, Inc. position peaked at $7.57M in Q4 2014.
- 45 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2023.
Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.